TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04389281: X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma

Sponsor: Immunolight, LLC · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 52 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$5,403,552

Rescue Site Savings

+$3,581,424

Unlock Full NCT04389281 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04389281 Rescue Dossier →